Downes Kevin J, Glatt Brian S, Kanchwala Suhail K, Mick Rosemarie, Fraker Douglas L, Fox Kevin R, Solin Lawrence J, Bucky Louis P, Czerniecki Brian J
Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Cancer. 2005 Mar 1;103(5):906-13. doi: 10.1002/cncr.20851.
Skin-sparing mastectomy (SSM) followed by immediate reconstruction is an effective treatment option for patients with early-stage breast carcinoma, but its use in patients with more advanced disease is controversial.
A retrospective review was performed that included 38 consecutive patients with high-risk breast carcinoma who underwent SSM and immediate reconstruction (between July 1996 and January 2002). Tumor characteristics, type of reconstruction, margin status, timing of adjuvant therapy, postoperative complications, and incidence of recurrence were evaluated.
High-risk patients (Stage IIA [n=4 patients] Stage IIB [n=23 patients] Stage IIIA [n=8 patients] and Stage IIIB [n=3 patients]) underwent immediate reconstruction after SSM with the use of a transverse rectus abdominis myocutaneous flap (n=31 patients), a latissimus dorsi myocutaneous flap plus an implant (n=3 patients), or tissue expanders with subsequent implant placement (n=4 patients). The median follow-up was 52.9 months (range, 27.5-92.0 months), and the median time to recurrence has not yet been reached at the time of last follow-up. The median interval from surgery to the initiation of postoperative adjuvant therapy was 38 days (range, 25-238 days). Local recurrence was seen in 1 patient (2.6%), systemic recurrence in was seen in 10 patients (26.3%), and both local and distant metastases in were seen in 2 other patients (5.3%).
SSM with immediate reconstruction appeared to be an oncologically safe treatment option for high-risk patients with advanced stages of breast carcinoma. In addition to the aesthetic and psychological benefits of performing SSM with immediate reconstruction, local recurrence rates and disease-free survival were favorable when combined with the use of radiation therapy and adjuvant chemotherapy, as indicated.
保留皮肤的乳房切除术(SSM)联合即刻乳房重建是早期乳腺癌患者的一种有效治疗选择,但在疾病分期较晚的患者中应用存在争议。
进行了一项回顾性研究,纳入了38例连续接受SSM和即刻乳房重建的高危乳腺癌患者(1996年7月至2002年1月期间)。评估了肿瘤特征、重建类型、切缘状态、辅助治疗时机、术后并发症及复发率。
高危患者(IIA期[n = 4例]、IIB期[n = 23例]、IIIA期[n = 8例]和IIIB期[n = 3例])在SSM后采用腹直肌肌皮瓣(n = 31例)、背阔肌肌皮瓣联合植入物(n = 3例)或组织扩张器随后植入植入物(n = 4例)进行即刻乳房重建。中位随访时间为52.9个月(范围:27.5 - 92.0个月),在最后一次随访时,中位复发时间尚未达到。从手术到开始术后辅助治疗的中位间隔时间为38天(范围:25 - 238天)。1例患者出现局部复发(2.6%),10例患者出现全身复发(26.3%),另外2例患者出现局部和远处转移(5.3%)。
SSM联合即刻乳房重建对于晚期高危乳腺癌患者似乎是一种肿瘤学上安全的治疗选择。除了SSM联合即刻乳房重建带来的美学和心理益处外,如所示,结合放疗和辅助化疗时,局部复发率和无病生存率良好。